Summit Therapeutics (SMMT) News Today $20.23 -0.46 (-2.20%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Analyst Initiates Coverage On 'Undervalued' Summit TherapeuticsMarch 24 at 2:17 PM | benzinga.comSummit Therapeutics (NASDAQ:SMMT) Earns Overweight Rating from Analysts at Cantor FitzgeraldMarch 24 at 2:35 AM | americanbankingnews.comIs Summit Therapeutics a Millionaire Maker?March 23 at 5:49 AM | fool.comSummit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Cantor FitzgeraldCantor Fitzgerald began coverage on shares of Summit Therapeutics in a research report on Friday. They set an "overweight" rating on the stock.March 22 at 8:26 AM | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by BrokeragesSummit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have givenMarch 22 at 4:11 AM | marketbeat.comSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | businesswire.comSummit Therapeutics initiated with an Overweight at Cantor FitzgeraldMarch 21, 2025 | markets.businessinsider.comSummit Therapeutics (SMMT) Gets a Buy from Cantor FitzgeraldMarch 21, 2025 | markets.businessinsider.comThis Unstoppable Biotech Stock Just Became an Even Better BuyMarch 19, 2025 | msn.comSkandinaviska Enskilda Banken AB publ Takes Position in Summit Therapeutics Inc. (NASDAQ:SMMT)Skandinaviska Enskilda Banken AB publ bought a new position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 32,663 shares of the company's stock, valued at approximately $586,000. Several other hedgMarch 18, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its stake in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 3.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,485,072 shares of the company's stocMarch 18, 2025 | marketbeat.comRobert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial OfficerMarch 17, 2025 | businesswire.comBank of New York Mellon Corp Has $5.95 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)Bank of New York Mellon Corp lifted its holdings in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 33.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 333,510 shares of the company's stMarch 17, 2025 | marketbeat.comSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 14, 2025 | businesswire.comWhy Summit Therapeutics Stock Was Winning This WeekMarch 14, 2025 | fool.comIs Summit Therapeutics Inc. (SMMT) the Best Multibagger Stock to Buy in 2025?March 13, 2025 | insidermonkey.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 9.5% - Here's What HappenedSummit Therapeutics (NASDAQ:SMMT) Shares Up 9.5% - Should You Buy?March 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated at Evercore ISIEvercore ISI started coverage on shares of Summit Therapeutics in a report on Wednesday. They issued an "outperform" rating and a $30.00 target price on the stock.March 13, 2025 | marketbeat.comThis Could Be the Catalyst That Sends Summit Therapeutics' Stock Higher This YearMarch 13, 2025 | fool.comSummit Therapeutics Inc. (SMMT): Why Are Analysts Bullish On This Hot Growth Stock Right Now?March 8, 2025 | msn.comSummit Therapeutics (NASDAQ:SMMT) Shares Down 5.7% - Should You Sell?Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.7% - Here's What HappenedMarch 8, 2025 | marketbeat.comE Fund Management Co. Ltd. Has $5.29 Million Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)E Fund Management Co. Ltd. grew its stake in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 5.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 296,299 shares of the company's stock after buying an additional 15,194March 7, 2025 | marketbeat.comSVB Wealth LLC Makes New $274,000 Investment in Summit Therapeutics Inc. (NASDAQ:SMMT)SVB Wealth LLC bought a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 15,350 shares of the company's stock, valued at approxMarch 6, 2025 | marketbeat.comPrincipal Financial Group Inc. Acquires 147,003 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)Principal Financial Group Inc. grew its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 252.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 205,150 shares of the company's stock after purchasing an addMarch 5, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Rating Upgraded by StockNews.comStockNews.com upgraded Summit Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday.March 5, 2025 | marketbeat.comHandelsbanken Fonder AB Lowers Stock Position in Summit Therapeutics Inc. (NASDAQ:SMMT)Handelsbanken Fonder AB reduced its stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 57.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,100 shares of thMarch 2, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 6.3% - Time to Buy?Summit Therapeutics (NASDAQ:SMMT) Shares Up 6.3% - Time to Buy?March 1, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at The Goldman Sachs GroupThe Goldman Sachs Group began coverage on Summit Therapeutics in a research report on Friday. They set a "buy" rating and a $42.00 price target on the stock.March 1, 2025 | marketbeat.comEquities Analysts Offer Predictions for SMMT Q1 EarningsSummit Therapeutics Inc. (NASDAQ:SMMT - Free Report) - Investment analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Summit Therapeutics in a research report issued to clients and investors on Tuesday, February 25th. HC Wainwright analyst M. Kapoor now forecasts thatMarch 1, 2025 | marketbeat.comGoldman starts Summit Therapeutics with a Buy on ivonescimab potentialFebruary 28, 2025 | markets.businessinsider.comSummit Therapeutics (NASDAQ:SMMT) Cut to Sell at StockNews.comStockNews.com cut shares of Summit Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday.February 26, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $44.00 target price on shares of Summit Therapeutics in a research report on Tuesday.February 25, 2025 | marketbeat.comSummit Therapeutics jumps 5% to $23.19 after trial pact with PfizerFebruary 25, 2025 | markets.businessinsider.comAkeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCsFebruary 24, 2025 | prnewswire.comSummit Therapeutics shares rise on Pfizer trial collaborationFebruary 24, 2025 | in.investing.comSummit Therapeutics announces clinical trial collaboration with PfizerFebruary 24, 2025 | markets.businessinsider.comSummit Therapeutics: Mid-2025 NSCLC Data Could Further Entrench Ivonescimab ProgramFebruary 24, 2025 | seekingalpha.comSummit Therapeutics Stock Sinks as Firm Reports Widening LossFebruary 24, 2025 | msn.comIs Summit Therapeutics (SMMT) One of the Best Growth Stocks to Invest In According to Analysts?February 24, 2025 | insidermonkey.comSummit Therapeutics (NASDAQ:SMMT) Trading Down 15.6% - Should You Sell?Summit Therapeutics (NASDAQ:SMMT) Shares Down 15.6% - Should You Sell?February 24, 2025 | marketbeat.comSummit Therapeutics Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 24, 2025 | seekingalpha.comSummit Therapeutics (NASDAQ:SMMT) Releases Quarterly Earnings ResultsSummit Therapeutics (NASDAQ:SMMT - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08).February 24, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Announces Quarterly Earnings Results, Hits ExpectationsSummit Therapeutics (NASDAQ:SMMT - Get Free Report) posted its earnings results on Monday. The company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08).February 24, 2025 | marketbeat.comSummit Therapeutics reports Q4 EPS (7c), consensus (6c)February 24, 2025 | markets.businessinsider.comHealthInvest Partners AB Buys 15,164 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)HealthInvest Partners AB lifted its stake in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 17.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 101,177 shares of the company's stock after buying an additional 1February 24, 2025 | marketbeat.comSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024February 24, 2025 | businesswire.comWorld Equity Group Inc. Buys 13,992 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)World Equity Group Inc. increased its stake in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 94.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,834 shares of the cFebruary 24, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSummit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the cFebruary 24, 2025 | marketbeat.comInsider Stock Buying Reaches US$78.8m On Summit TherapeuticsFebruary 23, 2025 | finance.yahoo.comSummit Therapeutics (NASDAQ:SMMT) Trading Up 6.8% - Time to Buy?Summit Therapeutics (NASDAQ:SMMT) Shares Up 6.8% - Here's What HappenedFebruary 21, 2025 | marketbeat.com Remove Ads Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address SMMT Media Mentions By Week SMMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SMMT News Sentiment▼0.700.63▲Average Medical News Sentiment SMMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SMMT Articles This Week▼105▲SMMT Articles Average Week Remove Ads Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today Beigene News Today BioNTech News Today Teva Pharmaceutical Industries News Today Intra-Cellular Therapies News Today Moderna News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SMMT) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SMMT Stock Free SMMT Stock Alerts